Disclosed is a method for treating osteoarthritis comprising a step of administering a patch to a patient. The patch comprises a backing layer and an adhesive layer laminated on the backing layer, the adhesive layer comprises an adhesive base, diclofenac sodium, dimethyl sulfoxide, and an organic acid, and a content of the organic acid is 6 mass % to 8 mass % with respect to a total mass of the adhesive layer. The patch is applied to an affected part once a day, and a dose of diclofenac sodium per administration is 70 mg to 150 mg.

The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Disclosed is a transdermal patch for treating osteoarthritis. The transdermal patch comprises a support layer and an adhesive layer laminated on the support layer. The adhesive layer includes an adhesive base, diclofenac sodium, dimethyl sulfoxide, and an organic acid. The organic acid content is 6-8 mass % of the total mass of the adhesive layer. The transdermal patch is applied once daily to an affected part and the dosage of diclofenac sodium per application is 70-150 mg.

A drug-in-adhesive device for transdermal delivery of cannabinoids to the bloodstream utilizes a decal-style temporary tattoo as the backing layer. The temporary tattoo is printed with colors and designs to create an aesthetically pleasing appearance that is more attractive than a typical transdermal patch backing layer. The tattoo includes a water-based drug-in-adhesive compound sandwiched between a release liner and a backing layer made from water release transfer paper with an inkjet-printed design. When the drug-in-adhesive compound adheres to the skin, the cannabinoids diffuse from the adhesive compound through the stratum corneum layer of the skin, through the dermis, and into the microvascular system of the body.

An adhesive patch assembly and method for making same. The assembly can include an adhesive patch and a release liner. The patch can include a backing and a skin-contact adhesive. The release liner can further include a first portion and a second portion separated by a hinge. The first portion can be positioned to overlay the backing of the patch when the release liner is folded upon the hinge, and the second portion can be positioned to underlie the skin-contact adhesive of the patch. The method can include positioning the patch on the release liner, such that patch is located on one of the first portion and the second portion of the release liner; and folding the release liner about to locate the patch between the first portion and the second portion of the release liner.

A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60 wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.

Disclosed is an adhesive patch having a support and an adhesive agent layer laminated on the support, wherein the support consists of spunlace nonwoven fabric, the adhesive agent layer comprises an SIS block copolymer and liquid paraffin, the adhesive patch has a first direction, which is a predetermined reference axis direction, and a second direction, which is orthogonal to the first direction, and a bending resistance in the first direction of the adhesive patch is 18 to 30 mm.

A therapeutic kinesiology tape includes a thin stretchable, elastic substrate having a first side and a second side, and an active layer disposed on the first side of the elastic substrate. The active layer has an adhesive characteristic and includes a cannabis-based mixture. In an embodiment, the cannabis-based mixture is delivered through the skin via a plurality of small-needle arrays. The kinesiology tape is available in continuous rolls and also pre-cut strips. Additionally, permanent magnets (e.g., healing magnets, acupressure magnets) may be added to the tape.

The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.